1. A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019
- Author
-
Julio A, Chirinos, Patricio, Lopez-Jaramillo, Evangelos J, Giamarellos-Bourboulis, Gonzalo H, Dávila-Del-Carpio, Abdul Rahman, Bizri, Jaime F, Andrade-Villanueva, Oday, Salman, Carlos, Cure-Cure, Nelson R, Rosado-Santander, Mario P, Cornejo Giraldo, Luz A, González-Hernández, Rima, Moghnieh, Rapti, Angeliki, María E, Cruz Saldarriaga, Marcos, Pariona, Carola, Medina, Ioannis, Dimitroulis, Charalambos, Vlachopoulos, Corina, Gutierrez, Juan E, Rodriguez-Mori, Edgar, Gomez-Laiton, Rosa, Cotrina Pereyra, Jorge Luis, Ravelo Hernández, Hugo, Arbañil, José, Accini-Mendoza, Maritza, Pérez-Mayorga, Charalampos, Milionis, Garyfallia, Poulakou, Gregorio, Sánchez, Renzo, Valdivia-Vega, Mirko, Villavicencio-Carranza, Ricardo J, Ayala-García, Carlos A, Castro-Callirgos, Rosa M, Alfaro Carrasco, Willy, Garrido Lecca Danos, Tiffany, Sharkoski, Katherine, Greene, Bianca, Pourmussa, Candy, Greczylo, Juan, Ortega-Legaspi, Douglas, Jacoby, Jesse, Chittams, Paraskevi, Katsaounou, Zoi, Alexiou, Styliani, Sympardi, Nancy K, Sweitzer, Mary, Putt, Jordana B, Cohen, and Pedro Antonio, Segura-Saldaña
- Subjects
Adult ,Male ,Fenofibrate ,SARS-CoV-2 ,Humans ,COVID-19 ,Female ,PPAR alpha ,Middle Aged ,Lipid Metabolism ,Aged - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cytotoxicity may involve inhibition of peroxisome proliferator-activated receptor alpha. Fenofibrate activates peroxisome proliferator-activated receptor alpha and inhibits SARS-CoV-2 replication in vitro. Whether fenofibrate can be used to treat coronavirus disease 2019 (COVID-19) infection in humans remains unknown. Here, we randomly assigned inpatients and outpatients with COVID-19 within 14 d of symptom onset to 145 mg of oral fenofibrate nanocrystal formulation versus placebo for 10 d, in a double-blinded fashion. The primary endpoint was a severity score whereby participants were ranked across hierarchical tiers incorporating time to death, mechanical ventilation duration, oxygenation, hospitalization and symptom severity and duration. In total, 701 participants were randomized to fenofibrate (n = 351) or placebo (n = 350). The mean age of participants was 49 ± 16 years, 330 (47%) were female, mean body mass index was 28 ± 6 kg/m
- Published
- 2022